Invivyd (IVVD) Retained Earnings (2020 - 2026)
Invivyd's (IVVD) quarterly Retained Earnings came in at -$1.0 billion in Q2 2026, down 11.51% on a YoY basis from -$1.2 billion in Q2 2025, and down 8.99% quarter-over-quarter from -$954.5 million in Q4 2025.
Analysis
Invivyd (IVVD) Retained Earnings (2020 - 2026) Analysis & Trends
Invivyd (IVVD) has reported Retained Earnings for 7 consecutive years, with -$1.0 billion the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Retained Earnings fell 11.51% year-over-year to -$1.0 billion; the trailing twelve-month figure through Jun 2026 stood at -$1.0 billion (down 11.51% YoY), and the FY2025 full-year result was -$954.5 million, down 5.82% from the prior year.
- Retained Earnings retreated to -$1.0 billion in Q2 2026 per IVVD's latest filing, from -$954.5 million in the prior quarter.
- Across five years, Retained Earnings topped out at -$392.8 million in Q1 2022 and bottomed at -$1.0 billion in Q2 2026.
- Historically, Retained Earnings has averaged -$741.8 million across 5 years, with a median of -$775.6 million in 2024.
- The sharpest annual moves came in 2022 and 2025: Retained Earnings tumbled 198.45% in 2022, then fell 5.82% in 2025.
- Over 5 years, Retained Earnings stood at -$533.4 million in 2022, then plunged by 37.24% to -$732.1 million in 2023, then decreased by 23.21% to -$902.0 million in 2024, then decreased by 5.82% to -$954.5 million in 2025, then retreated by 8.99% to -$1.0 billion in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$1.0 billion, -$954.5 million, and -$943.4 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | -22.28 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 9.53 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 15.69 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 37.62 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 558.00 Mn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 5.10 Bn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | -6.33 Bn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 20.97 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Invivyd | 244.65 Mn | 84.57 Mn | 13.01 Mn | -1.04 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.04 Bn |
| Dec 31, 2025 | -954.48 Mn |
| Sep 30, 2025 | -943.41 Mn |
| Jun 30, 2025 | -932.94 Mn |
| Mar 31, 2025 | -918.30 Mn |
| Dec 31, 2024 | -901.99 Mn |
| Sep 30, 2024 | -883.60 Mn |
| Jun 30, 2024 | -822.81 Mn |
| Mar 31, 2024 | -775.60 Mn |
| Dec 31, 2023 | -732.07 Mn |
| Sep 30, 2023 | -658.42 Mn |
| Jun 30, 2023 | -619.00 Mn |
| Mar 31, 2023 | -568.75 Mn |
| Dec 31, 2022 | -533.43 Mn |
| Sep 30, 2022 | -488.90 Mn |
| Jun 30, 2022 | -443.80 Mn |
| Mar 31, 2022 | -392.80 Mn |
| Dec 31, 2021 | -292.11 Mn |
| Sep 30, 2021 | -209.10 Mn |
| Jun 30, 2021 | -148.70 Mn |